Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
987-78-0
Molecular formula
C14H26N4O11P2
Molecular weight
488.32 g/mol
Drug class
Cytidine-5-diphosphocholine (CDP-choline)phospholipid precursor and neuroactive nutrient
Mechanism of action
An intermediate in the Kennedy pathway for phosphatidylcholine synthesis. After administration it is metabolised to choline and cytidine/uridine, which enter phospholipid and nucleotide pools; proposed neuroprotective effects are not established as a single proven clinical mechanism.
Indications / reported uses
No broad FDA- or EMA-authorised therapeutic indication as a standalone medicine. It has been studied or marketed in some countries for stroke, cognitive impairment and neurological recovery, but such uses should be identified as jurisdiction-specific or investigational unless an applicable product label confirms them.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Citicoline Environmental Risk Assessment (ERA) (the Citicoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.